Abstract: The present disclosure provides methods of treating pancreatic cancer by administering a cationic liposomal formulation. Additional therapeutic agents or therapies may also be included.
Type:
Application
Filed:
February 24, 2022
Publication date:
February 2, 2023
Applicant:
SynCore Biotechnology Co., Ltd.
Inventors:
Ruey-Kuen Hsieh, Hui-Yuan Tseng, Sih-Ting Lin
Abstract: The present disclosure provides methods of treating breast cancer, including triple negative breast cancer. The methods disclosed herein comprise administering a cationic liposomal formulation containing one or more cationic lipids and a taxane to a subject in need thereof. The methods also include administering one or more non-liposomal formulations including one or more active agents.
Abstract: A method of treating refractory or resistant pancreatic cancer by administering: (i) a cationic liposomal formulation comprising one or more cationic lipids and a therapeutically effective amount of paclitaxel; or (ii) a cationic liposomal formulation comprising one or more cationic lipids and a therapeutically effective amount of paclitaxel, and a therapeutically effective amount of gemcitabine.
Type:
Application
Filed:
January 4, 2018
Publication date:
December 19, 2019
Applicant:
SynCore Biotechnology Co., Ltd
Inventors:
Ruey-Kuen Hsieh, Hui-Yuan Tseng, Sih-Ting Lin
Abstract: The present invention relates to the preparation of liposomes with enhanced loading capacity for pharmaceutically and/or diagnostically active agents and/or cosmetic agents which are substantially solubilized by the liposomal membranes, to liposome dispersions with enhanced stability with respect to release of the active agent and/or cosmetic agent from the liposomes obtainable by the process, and to pharmaceutical or cosmetic compositions comprising said stabilized liposome dispersions. The preparation may involve dehydration and rehydration steps of liposome dispersions which may be carried out by spray drying.
Abstract: The present disclosure provides methods of treating breast cancer, including triple negative breast cancer. The methods disclosed herein comprise administering a cationic liposomal formulation containing one or more cationic lipids and a taxane to a subject in need thereof. The methods also include administering one or more non-liposomal formulations including one or more active agents.
Abstract: The present invention relates to the use of pharmaceutical preparations comprising paclitaxel for administration to a human patient in need thereof.
Abstract: The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of “triple receptor negative” breast cancer.
Type:
Application
Filed:
June 12, 2017
Publication date:
September 28, 2017
Applicant:
SynCore Biotechnology Co., Ltd
Inventors:
Kay-Oliver Kliche, Axel Mescheder, Martine Piccart
Abstract: The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of “triple receptor negative” breast cancer.
Type:
Grant
Filed:
August 24, 2015
Date of Patent:
July 18, 2017
Assignee:
SYNCORE BIOTECHNOLOGY CO., LTD.
Inventors:
Kay-Oliver Kliche, Axel Mescheder, Martine Piccart